bjo.bmj22d
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Aims To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular ...
WebMD20d
Susvimo (ranibizumab) - Uses, Side Effects, and More
People who are allergic to any of the following should not use Susvimo. Susvimo Ranibizumab Any of the ingredients in the specific product dispensed Your pharmacist can tell you all of the ...
BMJ22d
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
Objective To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular ...
ophthalmologytimes2h
UK MHRA issues approval for aflibercept biosimilar FYB203 (AHZANTIVE) from Formycon
FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as ...
BMJ22d
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
Objectives To evaluate the cost-effectiveness of immediate treatment with ranibizumab in patients with neovascular age-related macular degeneration (nAMD) with good (better than 6/12) starting visual ...
PharmiWeb6h
Global Retinal Biologics Market to Reach USD 41.92 Billion by 2028 at a 11.1% of CAGR
Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow ...
The American Journal of Managed Care21d
FDA Approves Ranibizumab Implant in Treatment of DME
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
Business Wire21d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...
ophthalmologytimes21d
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
The refillable ocular implant delivers ranibizumab continuously, offering a convenient alternative to routine eye injections. Approval was based on the Phase III Pagoda study, demonstrating ...
PharmiWeb16h
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
clinicaladvisor.com7d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...
Pharm Exec21d
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye ...